<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396240</url>
  </required_header>
  <id_info>
    <org_study_id>D3560L00008</org_study_id>
    <secondary_id>ORBITAL</secondary_id>
    <nct_id>NCT00396240</nct_id>
  </id_info>
  <brief_title>ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals</brief_title>
  <official_title>ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin
      plus initiatives to improve compliance. If the subject does not reach the EAS LDL-C treatment
      goal at week 12, rosuvastatin will be titrated from 10mg to 20mg.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    study cancelled prior to FSI
  </why_stopped>
  <start_date>February 2002</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the rosuvastatin therapy (10mg daily, titrated to 20mg at 12 weeks if necessary), alone or in combination with enhanced compliance initiatives, at 6 months, in bringing subjects with prim. hypercholesterolaemia to the EAS LDL-C target goals</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of rosuvastatin, both with and without compliance initiatives on number and percentage of subjects within the EAS or local LDL-C and TC target goals after 12 week therapy,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment.</measure>
  </secondary_outcome>
  <enrollment>1294</enrollment>
  <condition>Primary Hypercholesterolaemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Initiatives to improve compliance</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary hypercholesterolaemia:

          -  Statin na√Øve subjects (LDL-C level &gt; 3.5 mmol/L) or subjects on an ineffective &quot;start
             dose&quot; of a lipid-lowering therapy (LDL-C level &gt; 3.1 mmol/L).

          -  CV risk &gt; 20%,

          -  history of CHD or other established atherosclerotic disease

        Exclusion Criteria:

          -  History of severe adverse events with another HMG-CoA reductase inhibitor

          -  Secondary hypercholesterolaemia;

          -  Unstable cardiovascular disease;

          -  Uncontrolled diabetes, active liver disease;

          -  Severe hepatic or renal impairment;

          -  Treatment with cyclosporin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madeleine Billeter, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Riesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Darioli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUV (Centre Hospitalier Universitaire Vaudois) Lausanne</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2006</study_first_submitted>
  <study_first_submitted_qc>November 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2006</study_first_posted>
  <last_update_submitted>March 25, 2009</last_update_submitted>
  <last_update_submitted_qc>March 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2009</last_update_posted>
  <keyword>rosuvastatin</keyword>
  <keyword>hypercholesterolaemia</keyword>
  <keyword>cholesterol</keyword>
  <keyword>LDL-C</keyword>
  <keyword>triglyceride</keyword>
  <keyword>plasma lipids</keyword>
  <keyword>compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

